Absorption of gold from injected sites occurs rapidly, reaching its peak in blood between 4 and 6 hours. In plasma, 95% of gold is bound to albumin. Three patients that were studied from the beginning of weekly therapy showed a progressive stepwise rise in plasma gold levels up to the sixth week. Ur
Activation of gold-reactive T lymphocytes in rheumatoid arthritis patients treated with gold
β Scribed by Jo Verwilghen; Gabrielle H. Kingsley; Lorraine Gambling; Gabriel S. Panayi
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 530 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
β¦ Synopsis
To assess the role of T lymphocyte sensitization in the etiology of side effects of gold therapy in patients with rheumatoid arthritis (RA).
Methods. Lymphocyte proliferation induced by gold(II1) and gold(1) salts was measured in 53 subjects: 30 RA patients with gold-induced side effects (17 with dermatitis, 9 with proteinuria, 3 with hematologic complications, and 1 with colitis), 9 RA patients without side effects despite prolonged chrysotherapy, 4 RA patients who had never received gold, and 10 healthy controls. Peripheral blood lymphocytes were cultured with the different gold salts and proliferation was measured by 3H-thymidine incorporation.
Results. Thirteen of the 17 RA patients who developed gold-induced dermatitis showed significant T lymphocyte proliferation in response to gold(1II) salts, and this proliferation could be completely blocked by monoclonal antibodies directed at the HLA-DR molecule. Such proliferative responses were not seen in patients with other gold-induced side effects, in patients who had never received gold, or in healthy controls. Only 1 of 9 patients who had not developed side effects
π SIMILAR VOLUMES
Table 1. Demographic and epidemiologic features in white rheumatoid arthritis patients receiving gold treatment Toxicity Number of patients Mean age 2 SD Mean age at onset \* SD (years) Mean duration of disease 2 SD (years) Males (%) Females 1%) Seropositive (%) Present Absent 38 59.8 2 11.5 45.0 2